Company: SHPH
Filing Date: 2025-05-28
Form Type: 8-K
Source: 0001641172-25-012536
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-05-28
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.

On
May 21, 2025, Shuttle Pharmaceutical Holdings, Inc.(the “ Company”), implemented a 70% salary reduction for salaried employees
and executive officers, including that of Christopher Cooper, the Company’s Interim Chief Executive Officer, Peter Dritschilo,
the Company’s President and Chief Operating Officer, Mira Jung, the Company’s Chief Scientific Officer, Tyvin Rich, the Company’s
Chief Clinical Officer, and Michael P. Vander Hoek, the Company’s Vice President, Regulatory. In addition, Timothy Lorber, the
Company’s Chief Financial Officer has agreed that 70% of this salary will be deferred and paid at a later time.

   2  

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  SHUTTLE                                                      
  Dated:                                                       
  By:                                 /s/                      
  Name:                               Christopher              
  Title:                              Interim                  

   3